This program explores treatment options for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic colorectal cancer (mCRC). To make informed decisions when treating patients with HER2-positive status, clinicians must understand using HER2 as a testing target and know the latest treatment options available. This activity raises clinician awareness of the impact of testing for HER2 status in patients with mCRC and of identifying patients with CRC who would benefit from HER2-directed therapies.